topotecan has been researched along with Carcinoma, Epidermoid in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 18 (50.00) | 29.6817 |
| 2010's | 10 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Brewster, WR; Burger, RA; Gatcliffe, TA; Kuo, JV; Monk, BJ; Shah, A; Tewari, KS | 1 |
| Deslandres, M; Guillemet, C; Hardy-Bessard, AC; Kurtz, JE; Largillier, R; Lavau-Denes, S; Paraiso, D; Pujade-Lauraine, E; Roemer-Becuwe, C; Weber, B | 1 |
| Bucci, F; Cincinelli, R; Croce, AC; Favini, E; Pisano, C; Supino, R; Tortoreto, M; Zuco, V; Zunino, F | 1 |
| Aozasa, K; Doki, Y; Ikeda, J; Makino, T; Mamat, S; Morii, E; Qiu, Y; Rahadiani, N; Tian, T; Wang, Y | 1 |
| Berros, JP; Blay, P; Coto, PP; Estrada, E; Fernandez, Y; Fra, J; Gonzalez, EE; Izquierdo, M; Jimenez, P; Lacave, AJ; Luque, M; Muñiz, I; Muriel, C; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Arase, H; Fukuoka, M; Ijima, T; Kudoh, S; Masuda, N; Matsui, K; Mukaiyama, A; Nakagawa, K; Negoro, S; Takada, M; Takeda, K; Yoshida, P | 1 |
| Fusco, E; Lorusso, D; Mainenti, S; Malaguti, P; Masciullo, V; Pietragalla, A; Scambia, G | 1 |
| Ahmed, A; Fracasso, PM; Fusco, N; McMeekin, DS; Rose, PG; Salani, R; Sill, MW; Wolfson, AH; Yamada, SD | 1 |
| Achilli, C; Benedetti Panici, P; Donato, VD; Marchetti, C; Palaia, I; Perniola, G | 1 |
| Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T | 1 |
| Babilonti, L; Cormio, G; Ditto, A; Franchi, M; Ghezzi, F; Giorda, G; Giudici, S; Grijuela, B; Lorusso, D; Lorusso, M; Raspagliesi, F; Scambia, G; Zanaboni, F | 1 |
| Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ | 1 |
| Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB | 1 |
| Murphy, BA | 1 |
| Brown, JM; Cao, H; Choi, CY; Faix, JD; Giaccia, AJ; Koong, AC; Le, QT; Nelson, DW; Sunar-Reeder, B; Zhu, Y | 1 |
| Abraham, S; Booth, B; Brave, M; Dagher, R; Farrell, A; Gobburu, J; Jiang, X; Justice, R; Pazdur, R; Ramchandani, R; Sridhara, R | 1 |
| Li, QY; Shao, JH; Xiang, Y; Yang, JZ | 1 |
| Ara, G; Boscia, RE; Holden, SA; Korbut, T; Teicher, BA | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Heuser, A; Sauer, R | 1 |
| Ensley, JF; Lew, D; Rodriguez, GI; Schuller, D; Smith, RE; Taylor, SA | 1 |
| Robert, F; Soong, SJ; Wheeler, RH | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Bosse, U; Falkiewicz, B; Klinke, F; Striehn, E; Vogt, U | 1 |
| Asbury, RF; Baez, L; Benson, AB; Falkson, CI; Graham, D; Lipsitz, S | 1 |
| Andersen, WA; Blessing, JA; Bookman, MA; Hanjani, P; Herzog, TJ | 1 |
| Conrad, M; Jacobson, JL; Ketchel, SJ; Kuebler, JP; Macdonald, JS; Mills, G; Rivkin, S; Taylor, S; Weiss, G | 1 |
| Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A | 1 |
| Ampil, F; Bell, MC; Davidson, SA; Mathis, JM | 1 |
| Burkey, B; Forastiere, A; Langer, C; Leong, T; Murphy, BA | 1 |
| Blessing, JA; Levenback, C; Moore, JL; Muderspach, LI | 1 |
| Donato, NJ; Ling, YH; Perez-Soler, R | 1 |
| Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
| Boothby, R; DeCesare, S; Fiorica, J; Grendys, E; Hoffman, M; Holloway, R; LaPolla, J; Ndubisi, B; Orr, J; Patel, J | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
4 review(s) available for topotecan and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan | 2005 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
20 trial(s) available for topotecan and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms | 2009 |
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Synergism; Female; Humans; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2009 |
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prospective Studies; Survival; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Survival Rate; Tissue Distribution; Topotecan; Treatment Outcome | 2010 |
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Topotecan; Uterine Cervical Neoplasms | 2012 |
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2013 |
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2003 |
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2004 |
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms | 2006 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Topotecan | 1996 |
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan | 1997 |
Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Topotecan | 2000 |
Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2000 |
A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Survival Analysis; Topotecan | 2000 |
Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Topotecan; Uterine Cervical Neoplasms | 2001 |
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Topotecan | 2001 |
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2001 |
Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms | 2002 |
12 other study(ies) available for topotecan and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Esophageal Neoplasms; Female; Flow Cytometry; Gene Silencing; Humans; Immunoenzyme Techniques; Male; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tissue Array Analysis; Topotecan; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Complete remission after neoadjuvant chemotherapy of an advanced vulvar cancer patient: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Topotecan; Vulvar Neoplasms | 2012 |
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms | 2012 |
A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Colorectal Neoplasms; DNA-Binding Proteins; Flavonoids; Genes, Reporter; Genetic Vectors; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Mice, Inbred SENCAR; Neoplasm Transplantation; Nuclear Proteins; Piperidines; Topotecan; Transcription Factors; Transfection; Transplantation, Heterologous | 2005 |
[Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan; Treatment Outcome; Young Adult | 2008 |
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance; Fibrosarcoma; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred C3H; Topotecan; Tumor Cells, Cultured | 1993 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Middle Aged; Pilot Projects; Topotecan; Tumor Cells, Cultured | 1999 |
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2000 |
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |